Wipfli Financial Advisors’s Novavax NVAX Stock Holding History

Wipfli Financial Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$15K	Buy	+841	New	+$36.4K	﹤0.01%	1692

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Wipfli Financial Advisors's NVAX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Novavax (NVAX) in Q3 2022: 841 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #1692 among its holdings.

253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Wipfli Financial Advisors held 841 shares of Novavax worth $15K as of Q3 2022.
Novavax was a new Wipfli Financial Advisors position in Q3 2022.
Novavax made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1692 holding.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.